
Plozasiran, an investigational RNA interference therapeutic, produced significant and durable reductions in triglyceride and ApoC-III levels in patients with severe hypertriglyceridemia, potentially reducing the risk of acute pancreatitis.


coremsg

In patients with severe hypertriglyceridemia who are at risk for acute pancreatitis, the drug brought about triglyceride reductions of more than 50% in the phase 2 SHASTA-2 study.

Substantial Triglyceride Reduction With Plozasiran

investigational-drug-plozasiran-demonstrates-substantial-triglyceride-reduction-in-patients-with-severe-hypertriglyceridemia


Investigational Drug Plozasiran Demonstrates Substantial Triglyceride Reduction in Patients with Severe Hypertriglyceridemia
